ADMA - ADMA Biologics up 4% after increasing 2022 revenue guidance

ADMA Biologics (NASDAQ:ADMA) is up 4% in after-hours trading after stating it is boosting its 2022 revenue guidance in light of revenue growth in Q1 2022. In its Q1 results, the specialty plasma-derived biologics company said it expects full-year revenue of at least $130M, up from $125M. Revenue in the quarter of $29.1M was an ~82.8% year-over-year increase and topped estimates. ADMA's net loss in the quarter widened 36% (-$0.13 per share, basic and diluted) to ~$25M compared to the prior-year period. Looking ahead, ADMA (ADMA) projects it could generate $250M in top-line revenue in 2024, and $300 million beyond then. In addition, it sees net income of $50M-$100M in 2024-2025 and beyond. Read why Seeking Alpha contributor Jeffrey Himelson considers ADMA (ADMA) a strong buy.

For further details see:

ADMA Biologics up 4% after increasing 2022 revenue guidance